Global ASCVD Trends & Emerging Strategies

Session 1: Evidence of LDL-C as a Cause of Atherosclerotic Cardiovascular Disease

Featuring Erin Bohula, MD, DPhil, & Jennifer Robinson, MD, MPH

Session 2: The Sad and Inadequate Reality of Cholesterol Control Worldwide

Featuring Raul Santos, MD, PhD, & Peter Libby, MD

Session 3: For ASCVD Prevention the Lower the LDL-C the Better

Featuring Michal Vrablik, MD, PhD, & William Brown, MD

Session 4: Safety of Intensive LDL-C Reduction

Featuring Ioanna Gouni-Berthold, MD, & Raul Santos, MD, PhD

Session 5: Impact of Blocking Circulating PCSK9 with Monoclonal Antibodies on Atherogenic Lipoprotein

Featuring Dirk Blom, MBChB, PhD, & Dong Zhao, MD, PhD

Session 6: Impact of PCSK9 Inhibition in very High-risk Patients and How to Increase Cost-effectiveness

Featuring Jennifer Robinson, MD, MPH, & Raul Santos, MD, PhD

Session 7: Efficacy, Feasibility & Safety of Early Use of Monoclonal PCSK9 Inhibitors – Acute Coronary Syndrome

Featuring Francois Mach, MD, PhD, & Hani Sabbour, MD, FACC

Session 8: Use of PCSK9 Inhibitors in Familial Hypercholesterolemia Patients

Featuring Mariko Shiba, MD, PhD, & Gerald Watts, MD, PhD

Session 9: Future Therapies for Dyslipidemia Treatment

Featuring Erin Michos, MD, MHS, & Peter Libby, MD